Companies / SFZN
SWXSiegfried Holding AG (SFZN) in our theses
Siegfried Holding AG appears in one of our theses. Below is why it entered the basket and how it has done since publication.
Washington threatens Brussels with pharma tariffs, and a new plant takes five years: the premium goes to lines already running in the US
Tariffs are pushing drug manufacturing into the US, but new plants won't come online until after 2030, so the pricing power lands with CDMOs that already have approved lines in America.
Why this company: A pure-play small-molecule contract manufacturer with an active-ingredient site in Pennsville, New Jersey. Tariffs cover APIs as well, so a US location turns from a cost into a selling point.
Where these numbers come from
The reference price is recorded on the thesis publication date and never changed afterwards. The current price is refreshed several times a day. Returns are in the listing currency and exclude dividends, so for dividend payers the real total return was somewhat higher.
This is not a recommendation to buy or sell. A company enters a basket as a beneficiary of the mechanism described in the thesis, and the full argument is on each thesis page.
See all of our theses
Each with a publication date, a causal map and a score assigned before the market ruled.
Open in Invesaro →